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CASE REPORT
Fig. 1. Multiple erythematous erosions in the oral cavity.
A Case of Cutaneous Side Effect of Methotrexate 
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Methotrexate (MTX) is an antimetabolite which interferes 
with DNA synthesis, and it is used for the treatment of 
moderate to severe psoriasis, atopic dermatitis and a wide 
variety of cutaneous diseases. Although many adverse effects 
of MTX, including cutaneous ulcerations, have been 
documented, multifocal mucosal ulceration mimicking 
Behçet’s disease has not been reported. In our case, a 
63-year-old female presented with oral, vaginal ulcer and 
multiple purpuric patches on both legs. Considering 
patient’s clinical course and histopathologic findings, we 
presumed that these reactions may be the side effect of MTX 
administered for treatment of necrotizing scleritis. Herein we 
report the cutaneous side effect of MTX that manifested 
clinically like Behçet’s disease. (Ann Dermatol 23(3) 412∼
414, 2011)
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INTRODUCTION
Methotrexate (MTX), a folic acid antagonist, has been 
widely used in dermatology to treat various diseases, such 
as moderate to severe psoriasis, psoriatic arthritis, and 
collagen vascular disease
1,2. This drug may cause various 
mucocutaneous adverse reactions, including mucositis, 
bone marrow depression, hepatitis, and renal insuffi-
ciency
3,4. Although development of skin ulceration in a 
small number of patients has been reported
5-7, multifocal 
mucocutaneous involvement, which shows similar clinical 
features with Behçet’s disease has not been reported. 
Herein we describe a 63-year-old woman with oral, 
genital ulcer and superficial thrombophlebitis or erythema 
multiforme-like lesions, which developed after administ-
ration of MTX. 
CASE REPORT
A 63-year-old woman presented with erythematous 
painful ulcers in the oral cavity and vulva, and multiple 
erythematous to purpuric crusted patches and papules on 
both legs. Five weeks ago, she presented with chief com-Cutaneous Side Effect of MTX Mimicking Behçet’s Disease
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Fig. 3. (A) Multiple erosive erythematous to purpuric crusted patches and papules on both legs. (B) Flattening of rete ridges, dyskeratotic
keratinocytes in the epidermis, and vacuolar degeneration and hyperpigmentation of basal cell layer. In the dermis, mild vascular 
proliferation and perivascular infiltration of lymphocytes were demonstrated. No evidence of vasculitis was seen (A: H&E ×100).
Fig. 2. Erythematous ulcers on the lower extremities.
plaints of loss of vision in the right eye. Her fundus 
examination was within normal limits. On anterior seg-
ment fluorescein and indocyanine green, the patient was 
diagnosed as having diffuse necrotizing scleritis. She 
started treatment with MTX (10 mg daily). Three weeks 
after starting the treatment with MTX, erythematous ulcers 
appeared in her oral cavity and vulva. Concomitantly, 
erosive erythematous crusted patches and papules 
appeared on both legs. The patient was referred to the 
department of dermatology for evaluation of Behçet’s dis
ease. A physical examination showed erythematous ulcers 
in her oral cavity (Fig. 1), vagina, and erosive erythema-
tous patches and papules on both lower legs (Fig. 2). 
Differential diagnosis included Behçet’s disease and 
cutaneous side effects of MTX. Laboratory tests showed 
hemoglobin of 8.3 g/dl, white blood cell count 1.99×10
3 
cells/mm
3 and platelet count 72×10
3/mm
3. Liver and 
renal function tests were normal. Antinuclear antibodies 
and HLA-B51 were positive and anti-ENA antibody group 
was negative. Pathergy test was also negative. Histopatho-
logical findings showed flattening of rete ridges and 
dykeratotic keratinocytes, vacuolar degeneration, and 
hyperpigmentation in the epidermis. In the dermis dense 
perivascular lympho-histiocytic infiltration was seen, 
without evidence of vasculitis (Fig. 3). Although systemic 
steroid (prednisolone 50 mg/day) was given in combi-
nation with colchicines for 1 week, there was no clinical 
improvement. After reducing the dose of MTX (7.5 mg, 
weekly twice) for a month and subsequently stopping the 
MTX and starting treatment with pyridoxine, the muco-
cutaneous lesions were healed completely. After 12 
months, there had been no recurrence of the lesions. 
Although the patient presented with oral and genital 
ulcers mimicking Behçet’s disease and HLA-B51 was HJ Lee, et al
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positive, the skin lesions showed significant correlation 
with the MTX treatment. Therefore we diagnosed the 
condition as acute cutaneous side effects of MTX. 
DISCUSSION
MTX (4-amino-4deoxy-10-methyl-pteroyl glutamic acid) is 
a folic acid analogue, and it blocks intracellular DNA 
synthesis
1-3. It is has been used successfully for over 50 
years for a wide variety of cutaneous diseases
4. This drug 
is approved for treatment of moderate to severe psoriasis, 
and cutaneous T cell lymphoma, and it has been known 
to be effective in many other dermatoses, including atopic 
dermatitis, vascular disease, and blistering disease
5-7. Rapidly 
proliferating cells are susceptible to MTX because most 
cells are in the S-phase, where this drug exerts its effects
1,4. 
Gastrointestinal mucosa, hair, and bone marrow are very 
susceptible to MTX because of the high rate of cellular 
turnover
3. Although cutaneous adverse reaction to MTX is 
not common, skin ulcerations, necrosis, erosions of the 
psoriatic plaques and bullous acral erythema, have been 
reported
3-6. 
In our case, the patient presented with oral, genital ulcers, 
and erythematous crusted patches. On initial physical exa-
mination, we suspected this case as Behçet’s disease. 
However, the evidence of neutrophilic vasculitis was not 
seen on histologic examination and pathergy test showed 
negative result. By further history taking, we learned that 
her mucocutaneous lesions had occurred after the trea-
ment with high-dose oral MTX. Laboratory findings showed 
pancytopenia, which suggested bone marrow suppression 
due to MTX. After stopping of MTX (7.5 mg, weekly 
twice), the mucocutaneous lesions were healed, and there 
has been no recurrence of the lesions for 12 months. 
Although the patient complained of ocular symptoms, 
scleritis is rarely associated with Behçet’s disease
8. Com-
bining histologic findings and clinical course, we dia-
gnosed the condition as acute cutaneous side effects of 
MTX.
MTX may cause direct cell toxicity, especially in tissues 
where cell turnover is increased, due to trauma or 
underlying dermatosis. Therefore in the literature, most 
cases of cutaneous ulcers showed some form of 
pre-existing cutaneous pathology, i.e. either physical 
insults or underlying dermatosis. However, in our case, 
the patient did not remember any remarkable history of 
trauma or other dermatosis in the area of the muco-
cutaneous lesion.
Our case is particular in that the patient showed similar 
clinical features to Behçet’s disease, such as oral, ocular 
and genital lesions and superficial thrombophlebitis or 
erythema multiforme-like lesions. Hence, we report a case 
of cutaneous side effects of MTX that mimicked Behçet’s 
disease. 
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